| Year |
Citation |
Score |
| 2024 |
Peshoff MM, Gupta P, Oberai S, Trivedi R, Katayama H, Chakrapani P, Dang M, Migliozzi S, Gumin J, Kadri DB, Lin JK, Milam NK, Maynard ME, Vaillant BD, Parker-Kerrigan B, ... ... Huse JT, et al. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Neuro-Oncology. PMID 38237157 DOI: 10.1093/neuonc/noad257 |
0.323 |
|
| 2024 |
Gubbiotti MA, Weinberg JS, Weathers SP, Dasgupta P, Tom MC, Aldape K, Quezado M, Abdullaev Z, Huse JT, Ballester LY. An incidental finding of a high-grade glioma with pleomorphic and pseudopapillary features (HPAP) with PBRM1 mutation. Journal of Neuropathology and Experimental Neurology. PMID 38164987 DOI: 10.1093/jnen/nlad114 |
0.319 |
|
| 2023 |
Shiau CK, Lu L, Kieser R, Fukumura K, Pan T, Lin HY, Yang J, Tong EL, Lee G, Yan Y, Huse JT, Gao R. High throughput single cell long-read sequencing analyses of same-cell genotypes and phenotypes in human tumors. Nature Communications. 14: 4124. PMID 37433798 DOI: 10.1038/s41467-023-39813-7 |
0.369 |
|
| 2023 |
Peshoff MM, Gupta P, Trivedi R, Oberai S, Chakrapani P, Dang M, Milam N, Maynard ME, Vaillant BD, Huse JT, Wang L, Clise-Dwyer K, Bhat KP. Triggering receptor expressed on myeloid cells 2 (TREM2) regulates phagocytosis in glioblastoma. Biorxiv : the Preprint Server For Biology. PMID 37066184 DOI: 10.1101/2023.04.05.535792 |
0.354 |
|
| 2023 |
Ozkizilkaya HI, Johnson JM, O'Brien BJ, McCutcheon IE, Prabhu SS, Ghia AJ, Fuller GN, Huse JT, Ballester LY. Intracranial mesenchymal tumor, FET::CREB fusion-positive in the lateral ventricle. Neuro-Oncology Advances. 5: vdad026. PMID 37051329 DOI: 10.1093/noajnl/vdad026 |
0.328 |
|
| 2023 |
Jahedi A, Kumar G, Kannan L, Agarwal T, Huse J, Bhat K, Kannan K. Gibbs process distinguishes survival and reveals contact-inhibition genes in Glioblastoma multiforme. Plos One. 18: e0277176. PMID 36795646 DOI: 10.1371/journal.pone.0277176 |
0.323 |
|
| 2023 |
Shiau CK, Lu L, Kieser R, Fukumura K, Pan T, Lin HY, Yang J, Tong EL, Lee G, Yan Y, Huse JT, Gao R. Delineating genotypes and phenotypes of individual cells from long-read single cell transcriptomes. Biorxiv : the Preprint Server For Biology. PMID 36778278 DOI: 10.1101/2023.01.24.525264 |
0.365 |
|
| 2022 |
Varn FS, Johnson KC, Martinek J, Huse JT, Nasrallah MP, Wesseling P, Cooper LAD, Malta TM, Wade TE, Sabedot TS, Brat D, Gould PV, Wöehrer A, Aldape K, Ismail A, et al. Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell. PMID 35649412 DOI: 10.1016/j.cell.2022.04.038 |
0.414 |
|
| 2022 |
Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A, Krishnan SN, Varn FS, Arrieta VA, Gupta P, Ferguson SD, ... Huse JT, et al. Central nervous system immune interactome is function of cancer lineage, tumor microenvironment and STAT3 expression. Jci Insight. PMID 35316217 DOI: 10.1172/jci.insight.157612 |
0.349 |
|
| 2022 |
Whitfield BT, Huse JT. Classification of adult-type diffuse gliomas: Impact of the World Health Organization 2021 update. Brain Pathology (Zurich, Switzerland). e13062. PMID 35289001 DOI: 10.1111/bpa.13062 |
0.367 |
|
| 2022 |
Dharmaiah S, Huse JT. The epigenetic dysfunction underlying malignant glioma pathogenesis. Laboratory Investigation; a Journal of Technical Methods and Pathology. PMID 35152274 DOI: 10.1038/s41374-022-00741-7 |
0.344 |
|
| 2021 |
Varn F, Johnson K, Wade T, Malta T, Sabedot T, Barthel F, Kim H, Ahmed N, Datta I, Barnholtz-Sloan J, Bakas S, D'Angelo F, Gan H, Garofano L, Huse J, et al. EPCO-09. LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT Neuro-Oncology. 23: vi3-vi3. DOI: 10.1093/neuonc/noab196.008 |
0.373 |
|
| 2021 |
Aaroe A, Ou A, McGovern S, Paulino A, Johnson J, Huse J, Fuller G, de Groot J, Walter A, Zaky W. RARE-23. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR: A CASE SERIES Neuro-Oncology. 23: i45-i45. DOI: 10.1093/neuonc/noab090.184 |
0.368 |
|
| 2020 |
Lattier JM, De A, Chen Z, Morales JE, Lang FF, Huse JT, McCarty JH. Megalencephalic leukoencephalopathy with subcortical cysts 1 (MLC1) promotes glioblastoma cell invasion in the brain microenvironment. Oncogene. PMID 33040087 DOI: 10.1038/s41388-020-01503-9 |
0.322 |
|
| 2020 |
Wang Y, Wild AT, Turcan S, Wu WH, Sigel C, Klimstra DS, Ma X, Gong Y, Holland EC, Huse JT, Chan TA. Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Science Advances. 6: eaaz3221. PMID 32494639 DOI: 10.1126/Sciadv.Aaz3221 |
0.311 |
|
| 2020 |
Hariharan S, Bowie M, Hostettler J, Roso K, He Y, Roskoski MA, Charbonneau C, Keir S, Brown M, Irvin D, Zhang G, Gromeier M, Huse J, Ashley D. IMMU-18. INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS Neuro-Oncology. 22: ii108-ii108. DOI: 10.1093/neuonc/noaa215.448 |
0.367 |
|
| 2020 |
Irvin D, Roberts H, Sharin V, Farooqi A, Dharmaiah S, Alvarez C, Huse J. CSIG-09. ATRX DEFICIENCY IN GLIOMA IMPACTS TRANSCRIPTIONAL PROFILES AND THE IMMUNE MICROENVIRONMENT IN VIVO Neuro-Oncology. 22: ii29-ii29. DOI: 10.1093/neuonc/noaa215.121 |
0.401 |
|
| 2019 |
Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, ... ... Huse JT, et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. PMID 31748746 DOI: 10.1038/S41586-019-1775-1 |
0.303 |
|
| 2019 |
Kaffes I, Szulzewsky F, Chen Z, Herting CJ, Gabanic B, Velázquez Vega JE, Shelton J, Switchenko JM, Ross JL, McSwain LF, Huse JT, Westermark B, Nelander S, Forsberg-Nilsson K, Uhrbom L, et al. Human Mesenchymal glioblastomas are characterized by an increased immune cell presence compared to Proneural and Classical tumors. Oncoimmunology. 8: e1655360. PMID 31646100 DOI: 10.1080/2162402X.2019.1655360 |
0.362 |
|
| 2019 |
Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro-Oncology. PMID 31276167 DOI: 10.1093/Neuonc/Noz119 |
0.316 |
|
| 2019 |
Hovinga KE, McCrea HJ, Brennan C, Huse J, Zheng J, Esquenazi Y, Panageas KS, Tabar V. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology. PMID 30680510 DOI: 10.1007/S11060-019-03102-5 |
0.302 |
|
| 2019 |
Mullan B, Qin T, Siada R, Ravindran R, Garcia T, Muruganand A, Harris M, Danussi C, Brosnan-Cashman J, Pratt D, Zhao X, Rehemtulla A, Sartor M, Venneti S, Meeker A, ... Huse J, et al. GENE-17. ATRX LOSS IN GLIOMA RESULTS IN EPIGENETIC DYSREGULATION OF THE G2/M CHECKPOINT AND SENSITIVITY TO ATM INHIBITION Neuro-Oncology. 21: vi101-vi101. DOI: 10.1093/Neuonc/Noz175.419 |
0.36 |
|
| 2019 |
Kassab C, Zamler D, Gupta P, Srinivasan V, Rao G, Prabhu S, Huse J, Fuller G, Bruner J, Langford L, McCutcheon I, Ferguson S, Weinberg J, Wistuba I, Lang F, et al. TMIC-60. COMPREHENSIVE SPATIAL CHARACTERIZATION OF IMMUNE CELLS IN THE CNS BRAIN TUMOR MICROENVIRONMENT Neuro-Oncology. 21: vi261-vi261. DOI: 10.1093/neuonc/noz175.1094 |
0.303 |
|
| 2018 |
Danussi C, Huse JT. Novel insights into the epigenetics of diffuse glioma. Molecular & Cellular Oncology. 5: e1472055. PMID 30263940 DOI: 10.1080/23723556.2018.1472055 |
0.302 |
|
| 2018 |
Jacobs DI, Fukumura K, Bainbridge MN, Armstrong GN, Tsavachidis S, Gu X, Doddapaneni HV, Hu J, Jayaseelan JC, Muzny DM, Huse JT, Bondy ML. Elucidating the molecular pathogenesis of glioma: integrated germline and somatic profiling of a familial glioma case series. Neuro-Oncology. PMID 30165405 DOI: 10.1093/Neuonc/Noy119 |
0.311 |
|
| 2018 |
Ballester LY, Glitza Oliva IC, Douse DY, Chen MM, Lan C, Haydu LE, Huse JT, Roy-Chowdhuri S, Luthra R, Wistuba II, Davies MA. Evaluating Circulating Tumor DNA From the Cerebrospinal Fluid of Patients With Melanoma and Leptomeningeal Disease. Journal of Neuropathology and Experimental Neurology. PMID 29873738 DOI: 10.1093/jnen/nly046 |
0.329 |
|
| 2018 |
Oldrini B, Curiel-García Á, Marques C, Matia V, Uluçkan Ö, Graña-Castro O, Torres-Ruiz R, Rodriguez-Perales S, Huse JT, Squatrito M. Somatic genome editing with the RCAS-TVA-CRISPR-Cas9 system for precision tumor modeling. Nature Communications. 9: 1466. PMID 29654229 DOI: 10.1038/s41467-018-03731-w |
0.353 |
|
| 2018 |
Danussi C, Bose P, Parthasarathy PT, Silberman PC, Van Arnam JS, Vitucci M, Tang OY, Heguy A, Wang Y, Chan TA, Riggins GJ, Sulman EP, Lang F, Creighton CJ, Deneen B, ... ... Huse JT, et al. Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling. Nature Communications. 9: 1057. PMID 29535300 DOI: 10.1038/S41467-018-03476-6 |
0.359 |
|
| 2017 |
Turcan S, Makarov V, Taranda J, Wang Y, Fabius AWM, Wu W, Zheng Y, El-Amine N, Haddock S, Nanjangud G, LeKaye HC, Brennan C, Cross J, Huse JT, Kelleher NL, et al. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence. Nature Genetics. PMID 29180699 DOI: 10.1038/S41588-017-0001-Z |
0.319 |
|
| 2017 |
Yan D, Kowal J, Akkari L, Schuhmacher AJ, Huse JT, West BL, Joyce JA. Inhibition of colony stimulating factor-1 receptor abrogates microenvironment-mediated therapeutic resistance in gliomas. Oncogene. PMID 28759044 DOI: 10.1038/Onc.2017.261 |
0.343 |
|
| 2017 |
Ballester LY, Huse JT, Tang G, Fuller GN. Molecular Classification of Adult Diffuse Gliomas: Conflicting IDH1/IDH2, ATRX and 1p/19q Results. Human Pathology. PMID 28549927 DOI: 10.1016/j.humpath.2017.05.005 |
0.317 |
|
| 2017 |
Huang Y, Rajappa P, Hu W, Hoffman C, Cisse B, Kim JH, Gorge E, Yanowitch R, Cope W, Vartanian E, Xu R, Zhang T, Pisapia D, Xiang J, Huse J, et al. A proangiogenic signaling axis in myeloid cells promotes malignant progression of glioma. The Journal of Clinical Investigation. PMID 28394259 DOI: 10.1172/Jci86443 |
0.367 |
|
| 2016 |
Rajappa P, Cobb WS, Vartanian E, Huang Y, Daly L, Hoffman C, Zhang J, Shen B, Yanowitch R, Garg K, Cisse B, Haddock S, Huse JT, Pisapia DJ, Chan TA, et al. Malignant astrocytic tumor progression potentiated by JAK-mediated recruitment of myeloid cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28039266 DOI: 10.1158/1078-0432.Ccr-16-1508 |
0.375 |
|
| 2016 |
Huse JT, Snuderl M, Jones DT, Brathwaite CD, Altman N, Lavi E, Saffery R, Sexton-Oates A, Blumcke I, Capper D, Karajannis MA, Benayed R, Chavez L, Thomas C, Serrano J, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathologica. PMID 27812792 DOI: 10.1007/S00401-016-1639-9 |
0.554 |
|
| 2016 |
Huse JT. Establishing a Robust Molecular Taxonomy for Diffuse Gliomas of Adulthood. Surgical Pathology Clinics. 9: 379-90. PMID 27523967 DOI: 10.1016/j.path.2016.04.005 |
0.345 |
|
| 2016 |
Oktay Y, Ülgen E, Can Ö, Akyerli CB, Yüksel Ş, Erdemgil Y, Durası IM, Henegariu OI, Nanni EP, Selevsek N, Grossmann J, Erson-Omay EZ, Bai H, Gupta M, Lee W, ... ... Huse JT, et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Scientific Reports. 6: 27569. PMID 27282637 DOI: 10.1038/Srep27569 |
0.345 |
|
| 2016 |
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, ... ... Huse J, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164: 550-563. PMID 26824661 DOI: 10.1016/J.Cell.2015.12.028 |
0.315 |
|
| 2016 |
Dalvi N, Kleinerman R, Huse J, Abramson D, Dunkel I. LG-36LOW GRADE ASTROCYTOMA: A RARE SECOND TUMOR IN RETINOBLASTOMA SURVIVORS Neuro-Oncology. 18: iii86.4-iii86. DOI: 10.1093/neuonc/now075.36 |
0.366 |
|
| 2015 |
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, ... ... Huse JT, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. The New England Journal of Medicine. 372: 2499-508. PMID 26061753 DOI: 10.1056/Nejmoa1407279 |
0.383 |
|
| 2015 |
Huse JT, Rosenblum MK. The Emerging Molecular Foundations of Pediatric Brain Tumors. Journal of Child Neurology. PMID 25873586 DOI: 10.1177/0883073815579709 |
0.316 |
|
| 2015 |
Venneti S, Huse JT. The evolving molecular genetics of low-grade glioma. Advances in Anatomic Pathology. 22: 94-101. PMID 25664944 DOI: 10.1097/PAP.0000000000000049 |
0.476 |
|
| 2015 |
Omuro AMP, Zehir A, Cheng DT, Berger MF, Hyman DM, Solit DB, Baselga J, Ladanyi M, Arcila ME, Hameed M, Sabbatini P, DeAngelis LM, Gutin PH, Rosenblum M, Mellinghoff IK, ... ... Huse JT, et al. Is Next Generation Sequencing (NGS) Ready for Routine Clinical Practice in Gliomas? Results of a Prospective Study Utilizing the MSK-IMPACT Assay Journal of Clinical Oncology. 33: 2057-2057. DOI: 10.1200/Jco.2015.33.15_Suppl.2057 |
0.322 |
|
| 2015 |
Akkari L, Quail DF, Quick ML, Huse JT, Sutton JC, Joyce JA. Abstract A33: Combinatorial targeting of tumor-associated macrophages/ microglia and radiotherapy in gliomas Brain. 75. DOI: 10.1158/1538-7445.Brain15-A33 |
0.323 |
|
| 2015 |
Youland R, Remonde D, Caron A, Mladek A, Decker P, Sicotte H, Lachance D, Kipp B, Eckel-Passow J, Huse J, Giannini C, Jenkins R, Sarkaria J. GENO-37MOLECULAR PROFILING OF LONG-TERM SURVIVORS OF GLIOBLASTOMA Neuro-Oncology. 17: v100-v100. DOI: 10.1093/Neuonc/Nov215.37 |
0.343 |
|
| 2015 |
Danussi C, Bose P, Parthasarathy P, Turcan S, Picketts D, Chan T, Huse J. Epig-06Atrx Deficiency Promotes Migratory Behavior In Glioma Cells Of Origin By Dysregulating Genome-Wide Chromatin Accessibility And Modulating Transcriptional Programs. Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov214.06 |
0.302 |
|
| 2014 |
Huse JT, Aldape KD. The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5601-11. PMID 25398843 DOI: 10.1158/1078-0432.CCR-14-0831 |
0.311 |
|
| 2014 |
Ortiz B, Fabius AW, Wu WH, Pedraza A, Brennan CW, Schultz N, Pitter KL, Bromberg JF, Huse JT, Holland EC, Chan TA. Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. Proceedings of the National Academy of Sciences of the United States of America. 111: 8149-54. PMID 24843164 DOI: 10.1073/Pnas.1401952111 |
0.314 |
|
| 2014 |
Cairncross JG, Wang M, Jenkins RB, Shaw EG, Giannini C, Brachman DG, Buckner JC, Fink KL, Souhami L, Laperriere NJ, Huse JT, Mehta MP, Curran WJ. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 783-90. PMID 24516018 DOI: 10.1200/Jco.2013.49.3726 |
0.37 |
|
| 2014 |
Huang Y, Hoffman C, Rajappa P, Kim JH, Hu W, Huse J, Tang Z, Li X, Weksler B, Bromberg J, Lyden DC, Greenfield JP. Oligodendrocyte progenitor cells promote neovascularization in glioma by disrupting the blood-brain barrier. Cancer Research. 74: 1011-21. PMID 24371228 DOI: 10.1158/0008-5472.Can-13-1072 |
0.32 |
|
| 2014 |
Kastenhuber ER, Huse JT, Berman SH, Pedraza A, Zhang J, Suehara Y, Viale A, Cavatore M, Heguy A, Szerlip N, Ladanyi M, Brennan CW. Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathologica. 127: 747-59. PMID 24292886 DOI: 10.1007/s00401-013-1217-3 |
0.328 |
|
| 2014 |
Eckel-Passow J, Lachance D, Walsh K, Decker P, Sicotte H, Pekmezci M, Molinaro A, Rice T, Kosel M, Smirnov I, Sarkar G, Caron A, Kollmeyer T, Giannini C, Huse J, et al. GE-09 * TERT PROMOTER MUTATION, IDH MUTATION AND 1p/19q CODELETION DEFINE FIVE GLIOMA MOLECULAR GROUPS WITH SPECIFIC CLINICAL CHARACTERISTICS AND GERMLINE VARIANT ASSOCIATIONS Neuro-Oncology. 16: v98-v98. DOI: 10.1093/Neuonc/Nou256.9 |
0.36 |
|
| 2014 |
Cairncross G, Wang M, Jenkins R, Shaw E, Giannini C, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Huse JT, Mehta M. BENEFICIAL OUTCOMES AFTER PCV PLUS RT IN OLIGODENDROGLIAL TUMORS ARE ASSOCIATED WITH DETECTION OR RISK OF AN IDH MUTATION Neuro-Oncology. 16: iii44-iii45. DOI: 10.1093/neuonc/nou209.11 |
0.33 |
|
| 2013 |
Turcan S, Fabius AW, Borodovsky A, Pedraza A, Brennan C, Huse J, Viale A, Riggins GJ, Chan TA. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 4: 1729-36. PMID 24077826 DOI: 10.18632/Oncotarget.1412 |
0.401 |
|
| 2013 |
Ho AS, Kannan K, Roy DM, Morris LG, Ganly I, Katabi N, Ramaswami D, Walsh LA, Eng S, Huse JT, Zhang J, Dolgalev I, Huberman K, Heguy A, Viale A, et al. The mutational landscape of adenoid cystic carcinoma. Nature Genetics. 45: 791-8. PMID 23685749 DOI: 10.1038/Ng.2643 |
0.363 |
|
| 2013 |
Venneti S, Felicella MM, Coyne T, Phillips JJ, Gorovets D, Huse JT, Kofler J, Lu C, Tihan T, Sullivan LM, Santi M, Judkins AR, Perry A, Thompson CB. Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas. Journal of Neuropathology and Experimental Neurology. 72: 298-306. PMID 23481705 DOI: 10.1097/Nen.0B013E3182898113 |
0.579 |
|
| 2013 |
Venneti S, Garimella MT, Sullivan LM, Martinez D, Huse JT, Heguy A, Santi M, Thompson CB, Judkins AR. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathology (Zurich, Switzerland). 23: 558-64. PMID 23414300 DOI: 10.1111/Bpa.12042 |
0.59 |
|
| 2013 |
Huse JT, Edgar M, Halliday J, Mikolaenko I, Lavi E, Rosenblum MK. Multinodular and vacuolating neuronal tumors of the cerebrum: 10 cases of a distinctive seizure-associated lesion. Brain Pathology (Zurich, Switzerland). 23: 515-24. PMID 23324039 DOI: 10.1111/Bpa.12035 |
0.537 |
|
| 2013 |
Venneti S, Garimella M, Sullivan L, Martinez D, Huse J, Heguy A, Santi M, Thompson C, Alexander J. Abstract A01: Evaluation of H3K27me3 and EZH2 in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant GBM Cancer Research. 73. DOI: 10.1158/1538-7445.Cec13-A01 |
0.48 |
|
| 2012 |
Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, et al. The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell. 22: 765-80. PMID 23238013 DOI: 10.1016/J.Ccr.2012.11.005 |
0.318 |
|
| 2012 |
Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget. 3: 1194-203. PMID 23104868 DOI: 10.18632/Oncotarget.689 |
0.397 |
|
| 2012 |
Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2490-501. PMID 22415316 DOI: 10.1158/1078-0432.Ccr-11-2977 |
0.338 |
|
| 2012 |
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, ... ... Huse JT, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483: 479-83. PMID 22343889 DOI: 10.1038/Nature10866 |
0.327 |
|
| 2012 |
Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response. Proceedings of the National Academy of Sciences of the United States of America. 109: 3041-6. PMID 22323597 DOI: 10.1073/pnas.1114033109 |
0.309 |
|
| 2012 |
Brognaro E, Ghods A, Feinstein D, Glick R, Connolly KJ, Meetze K, Boudrow A, Gyuris J, Han M, Hingtgen S, Figueiredo J, Farrar C, Farrar C, Deubgen M, Martinez-Quintanilla J, ... ... Huse JT, et al. LAB-TUMOR MODELS (IN VIVO/IN VITRO) Neuro-Oncology. 14: vi160-vi164. DOI: 10.1093/Neuonc/Nos241 |
0.301 |
|
| 2011 |
Huse JT, Nafa K, Shukla N, Kastenhuber ER, Lavi E, Hedvat CV, Ladanyi M, Rosenblum MK. High frequency of IDH-1 mutation links glioneuronal tumors with neuropil-like islands to diffuse astrocytomas. Acta Neuropathologica. 122: 367-9. PMID 21755347 DOI: 10.1007/S00401-011-0855-6 |
0.565 |
|
| 2011 |
Fomchenko EI, Dougherty JD, Helmy KY, Katz AM, Pietras A, Brennan C, Huse JT, Milosevic A, Holland EC. Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. Plos One. 6: e20605. PMID 21754979 DOI: 10.1371/Journal.Pone.0020605 |
0.382 |
|
| 2011 |
Huse JT, Phillips HS, Brennan CW. Molecular subclassification of diffuse gliomas: seeing order in the chaos. Glia. 59: 1190-9. PMID 21446051 DOI: 10.1002/glia.21165 |
0.445 |
|
| 2010 |
Squatrito M, Brennan CW, Helmy K, Huse JT, Petrini JH, Holland EC. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell. 18: 619-29. PMID 21156285 DOI: 10.1016/j.ccr.2010.10.034 |
0.323 |
|
| 2009 |
Bleau AM, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle (Georgetown, Tex.). 8: 2936-44. PMID 19713741 |
0.324 |
|
| 2009 |
Perry A, Miller CR, Gujrati M, Scheithauer BW, Zambrano SC, Jost SC, Raghavan R, Qian J, Cochran EJ, Huse JT, Holland EC, Burger PC, Rosenblum MK. Malignant gliomas with primitive neuroectodermal tumor-like components: a clinicopathologic and genetic study of 53 cases. Brain Pathology (Zurich, Switzerland). 19: 81-90. PMID 18452568 DOI: 10.1111/J.1750-3639.2008.00167.X |
0.323 |
|
| Show low-probability matches. |